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Introduction
Within the bone marrow (BM) hematopoiesis occurs in
association with a complex stroma comprising a heterogeneous
population of non-haemopoietic cells including fibroblasts,
adipocytes, osteoblasts and other cellular elements of bone
(Bianco, 1998; Lichtman, 1981; Weiss, 1976). Although the
role played by BM stromal cells in the functional support of
hematopoiesis has been extensively investigated (Allen et al.,
1990; Dexter et al., 1977), other aspects of the biology of this
tissue remain poorly understood. In particular, precise
knowledge of the developmental relationship between the
various stromal elements of the BM, both during ontogeny and
in the postnatal organism, is currently lacking. Circumstantial
evidence for the existence of precursor cells for marrow
stromal tissue is provided by studies of the regeneration of BM
following ablation of the tissue by various means (Knospe et
al., 1972; Patt and Maloney, 1975) and by studies in rodents
demonstrating the development of a BM organ following
transplantation of BM to an ectopic site (Amsel and Dell, 1971;
Tavassoli and Crosby, 1968). 
A more direct demonstration of marrow stromal cell
precursors was provided by the pioneering studies of
Friedenstein and colleagues, who demonstrated the in vitro
growth of adherent colonies of cells morphologically
resembling fibroblasts (CFU-F) derived from explants of BM
(Castro-Malaspina et al., 1980; Friedenstein et al., 1970;
Owen, 1988). A consistent feature of marrow CFU-F-derived
colonies of virtually all species examined is their considerable
heterogeneity in terms of size, morphology, enzyme
histochemistry, proliferation and developmental potential
(Friedenstein et al., 1987; Kuznetsov et al., 1997; Owen and
Friedenstein, 1988). These observations are consistent with the
hypothesised existence within marrow stromal tissue of a
hierarchy of cellular differentiation supported at its apex by a
small compartment of self-renewing, pluripotent stromal stem
cells, known as bone marrow stromal cells, stromal precursor
cells, bone marrow stromal stem cells and mesenchymal stem
cells (Owen and Friedenstein, 1988).
The low incidence of clonogenic CFU-F in adult human BM
(range 1-20 · 105 mononuclear cells plated) (Gronthos and
Simmons, 1996) was a major limitation to their study, a
problem compounded until recently by the paucity of specific
antibody reagents to facilitate CFU-F isolation and enrichment.
Monoclonal antibody STRO-1 reacts with an as yet
unidentified cell surface antigen expressed by a minor
subpopulation of adult human BM (Simmons and Torok-Storb,
1991). Previous studies have shown that STRO-1 is non-
reactive with haematopoietic progenitors, but included within
the STRO-1+ population are essentially all detectable
clonogenic CFU-Fs (Simmons and Torok-Storb, 1991).
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Previous studies have provided evidence for the existence
of adult human bone marrow stromal stem cells (BMSSCs)
or mesenchymal stem cells. Using a combination of cell
separation techniques, we have isolated an almost
homogeneous population of BMSSCs from adult human
bone marrow. Lacking phenotypic characteristics of
leukocytes and mature stromal elements, BMSSCs are non-
cycling and constitutively express telomerase activity in
vivo. This mesenchymal stem cell population demonstrates
extensive proliferation and retains the capacity for
differentiation into bone, cartilage and adipose tissue in
vitro. In addition, clonal analysis demonstrated that
individual BMSSC colonies exhibit a differential capacity
to form new bone in vivo. These data are consistent with
the existence of a second population of bone marrow stem
cells in addition to those for the hematopoietic system. Our
novel selection protocol provides a means to generate
purified populations of BMSSCs for use in a range of
different tissue engineering and gene therapy strategies.
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Moreover, data from this laboratory demonstrate that within
the STRO-1+ fraction in adult human BM are BMSSCs with
the capacity to transfer a functional hematopoietic
microenvironment in vitro and for differentiation into multiple
stromal cell types including smooth muscle cells, adipocytes,
osteoblasts and chondrocytes (Dennis et al., 2002; Gronthos et
al., 1994; Simmons and Torok-Storb, 1991). However, use of
the STRO-1 antibody is not sufficient to obtain the purity of
BMSSCs required to properly study their properties, owing to
the presence of contaminating populations of glycophorin-A-
positive nucleated red cells and a small subset of B-
lymphocytes. 
Herein, we report the isolation of a highly enriched
population of BMSSCs with clonogenic potential from adult
human BM, on the basis of the use of STRO-1 in combination
with an antibody directed to vascular cell adhesion molecule-
1 (VCAM-1/CD106). In addition, we examine aspects of the
molecular, cellular and developmental properties of this poorly
characterized population of stromal stem cells. The isolation of
BMSSCs is a prerequisite for the study of mechanisms that
regulate their differentiation and is likely to be of therapeutic
importance given the developmental potential of these cells.
Materials and Methods
Subjects and cell culture
BM aspirates were obtained from the posterior iliac crest of normal
adult volunteers (20-35 years old) following informed consent,
according to procedures approved by the ethics committee of the
Royal Adelaide Hospital, South Australia. BM mononuclear cells
(BMMNC) were prepared as previously described (Gronthos and
Simmons, 1995). Primary BMSSC cultures were established in a -
MEM supplemented with 20% fetal calf serum and 100 m M L-
ascorbate-2-phosphate as previously described (Gronthos and
Simmons, 1995) for colony efficiency assays, RT-PCR,
immunohistochemistry and developmental studies. BMSSC clonal
cell lines were generated by limiting dilution from day 14 colonies
derived from STRO-1BRIGHT/VCAM-1+ sorted cells as described
below, following subculture in serum-replete medium for
proliferation, RT-PCR, imunohistochemistry and developmental
studies.
Primary antibodies
Monoclonal antibodies (MAbs) STRO-1 (mouse IgM) (Simmons and
Torok-Storb, 1991) and the anti-VCAM-1 antibody 6G10 (mouse
IgG1) (Simmons et al., 1992) were used as tissue culture supernatants
diluted 1:2 and 1:4, respectively. Isotype-matched controls of
irrelevant specificity, 1A6.12, (IgM), 3D3 (IgG1) and 1D4.5 (IgG2a)
(1/4; kindly provided by L. K. Ashman, Medical Science Building,
University of Newcastle, New South Wales, Australia). a -smooth
muscle actin (5 m g/ml, mouse IgG2a; Immunotech), affinity-purified
rabbit antiserum to collagen type I and rabbit immunoglogulin control
(1/200; Chemicon International Inc., Temecula, CA). Anti-Ki-67-
FITC or isotype-matched IgG1-FITC antibody (1/10; Dakopatts A/S,
Glostrup, Denmark).
Magnetic-activated cell sorting 
Magnetic-activated cell sorting (MACS) was performed as previously
described (Gronthos, 1998; Gronthos and Simmons, 1995). In brief,
approximately 1-3· 108 BMMNCs were sequentially incubated with
STRO-1 supernatant, anti-IgM-biotin, streptavidin microbeads and
finally streptavidin-FITC (Caltag Laboratories, Burlingame, CA)
before being separated on a Mini MACS magnetic column (Miltenyi
Biotec Inc., Auburn, CA). 
Fluorescence-activated cell sorting and limiting dilution assays
The STRO-1+ (FITC labelled) isolated by MACS was incubated with
purified an anti-VCAM-1 antibody 6G10 or isotype control 1B5 for
30 minutes on ice, washed and incubated with phycoerythrin (PE)-
conjugated goat anti-mouse IgG antibody (1/50; Southern
Biotechnology Associates, Birmingham, AL) for an additional 20
minutes on ice. Cells were sorted using a FACStarPLUS flow cytometer
(Becton Dickinson, Sunnyvale, CA). Limiting dilution assays were
performed with STRO-1BRIGHT/VCAM-1+ sorted cells seeded at
plating densities of 1, 2, 3, 4, 5 and 10 cells per well (96-well plates)
in replicates of 24 wells per plating density, using the automated cell
deposition unit (ACDU) of the flow cytometer. The cells were cultured
in serum-deprived medium in the presence of PDGF-BB and EGF (10
ng/ml) as previously described (Gronthos and Simmons, 1995).
Colony efficiency assays were performed using Poisson distribution
statistics by determining the number of wells with no clonogenic
growth at day 14 of culture following staining of the cultures with
0.1% (w/v) toluidine blue in 1% paraformaldehyde. Aggregates of
>50 cells were scored as CFU-F-derived colonies and aggregates of
>10 and <50 cells were scored as clusters. 
Analysis of cell cycle status
The STRO-1+ cells isolated by MACS were incubated with
streptavidin-PE (Caltag; 1:50) for 15 minutes on ice. After washing
with PBS, the cells were fixed for 10 minutes with 70% (v/v) ethanol
on ice. Following washing, the cells were incubated with either anti-
Ki-67-FITC or isotype-matched IgG1-FITC antibody for 45 minutes
on ice. The cells were then washed in PBS prior to flow cytometric
analysis.
Immunostaining
STRO-1BRIGHT/VCAM-1+ cells isolated by FACS were prepared as
cytospins and fixed with cold acetone. After washing, the cells were
blocked in 5% goat serum in PBS and then incubated with primary
antibodies and the corresponding control immunoglobulins. The
subsequent steps of immunoperoxidase staining were performed using
Vectastain ABC immunoperoxidase kits for mouse and rabbit IgG,
respectively (Vector Laboratories, Burlingame, CA) according to the
manufacturer’s instructions. 
Reverse transcriptase polymerase chain reaction analysis
Total cellular RNA was prepared from 2 · 104 STRO-1bright/VCAM-
1+ sorted cells collected as a bulk population and lysed using an
RNAzolB extraction method (Biotecx Lab. Inc., Houston, TX)
according to the manufacturer’s recommendations. RNA isolated from
each subpopulation was then used as a template for cDNA synthesis,
prepared using a First-strand cDNA synthesis kit (Pharmacia Biotech,
Uppsala, Sweden). The expression of various transcripts was assessed
by PCR amplification, using a standard protocol as described
previously (Gronthos et al., 1999). Primers sets used in this study are
shown in Table 1. Following amplification, each reaction mixture was
analysed by using 1.5% agarose gel electrophoresis and visualised by
ethidium bromide staining. RNA integrity was assessed by the
expression of GAPDH.
Differentiation of CFU-F in vitro
We have previously reported the conditions needed for human BM
stromal cells to develop a mineralized bone matrix in vitro as a MEM
supplemented with 10% FCS, 100 m M L-ascorbate-2-phosphate,
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dexamethasone 10–7 M and 3 mM inorganic phosphate (Gronthos et
al., 1994). Mineral deposits were identified by positive von Kossa
staining. Adipogenesis was induced in the presence of 0.5 mM
methylisobutylmethylxanthine, 0.5 m M hydrocortisone and 60 m M
indomethacin as previously described (Gimble, 1998). Oil Red O
staining was used to identify lipid-laden fat cells. Chondrogenic
differentiation was assessed in aggregate cultures treated with 10
ng/ml TGF-b 3 as described previously (Pittenger et al., 1999).
In vivo assay of bone formation
The adherent cells derived from STRO-1BRIGHT/VCAM-1+ cells at
passage two-three were trypsinised, mixed with 40 mg
hydroxyapatite/tricalcium phosphate ceramic particles (Zimmer
Corporation, Warsaw, IN) and then implanted into subcutaneous
pockets on the dorsal surface of two-month-old SCID mice as
described previously (Gronthos et al., 2000). These procedures were
performed in accordance with an approved animal protocol (Adelaide
University AEC# M/079/94). Implants were recovered after 6-8
weeks, fixed in 4% paraformaldehyde for 2 days, then decalcified for
a further 10 days in 10% EDTA prior to embedding in paraffin. For
histological analysis, 5 m m sections of the implants were prepared and
stained with haematoxylin and eosin. In situ hybridization for the
human specific alu sequence was performed as previously described
(Gronthos et al., 2000).
Telomerase repeat amplification protocol
Telomerase cell extracts prepared by the method of Kim et al. (Kim
et al., 1994) were analysed for the presence of telomerase activity as
previously described (Fong et al., 1997). To confirm the specificity of
the telomerase products 2 m l aliquots of each in CHAPS lysate was
subjected to denaturation and resolved on a non-denaturing 12%
polyacryalmide gel, then visualised by staining with SYBR green
fluorescent dye (FMC Bioproducts, OR) as recommended by the
manufacturer. The telomerase repeat amplification protocol (TRAP)
products were analysed using a FluorImager (Molecular Dynamics,
Sunnyvale, CA).
Transmission electron microscopy
Approximately 2· 104 STRO-1BRIGHT/VCAM-1+ cells were fixed in
2.5% glutaraldehyde (EM Grade) in cacodylate buffer and then
processed for embedding into resin as previously described (Gronthos
et al., 1994). Ultrathin sections were examined using a JEOL 1200
EX II (Tokyo, Japan) transmission electron microscope.
Results
Purification of stromal precursor cells (CFU-F) 
We elected to use the monoclonal antibody STRO-1 (Simmons
and Torok-Storb, 1991) as the basis of a strategy to
prospectively isolate clonogenic CFU-F. Immunoselection by
MACS yielded a population with 75.3% STRO-1+ cells±3.2
(n=20), whereas the incidence of STRO-1+ cells in the starting
BMMNC samples was 6.5%±0.73 (n=20). The STRO-1+
population exhibited a heterogeneous pattern of STRO-1
expression spanning four decades of fluorescence intensity,
with the majority of cells exhibiting low (STRO-1DULL) to
intermediate (STRO-1INT) levels of STRO-1 binding in
addition to a small but incompletely resolved subpopulation
characterised by very high level STRO-1 (STRO-1BRIGHT)
staining cells (Fig. 1A). STRO-1DULL, STRO-1INT and STRO-
1BRIGHT fractions were isolated by FACS and each population
assayed for its CFU-F content. The majority (74%) of CFU-
F were recovered in the minor STRO-1BRIGHT subpopulation
and correspondingly depleted or absent from the STRO-1DULL
and STRO-1INT fractions (Table 2). Selection of the STRO-
1BRIGHT fraction resulted in a 950-fold enrichment of CFU-F
relative to their incidence in unseparated BM mononuclear
cells (BMMNC) samples prior to MACS/FACS separation
(Table 2). 
To further increase the quantity of CFU-F, we made use of
previous studies that examined the expression of a broad range
of cell surface molecules on CFU-F (Simmons et al., 1994).
VCAM-1/CD106 was one of several cell surface molecules
that fulfilled the criteria of minimal reactivity with BMMNC
but produced a high yield of CFU-F following FACS. In accord
with these data, dual-color FACS analysis of MACS-isolated
STRO-1+ cells demonstrated VCAM-1 expression by a minor
subpopulation of cells (1.4%±0.3; n=20), which were
Table 1. PCR primer pairs used in this study
Accession 
Gene Primer sets number
GAPDH Forward: 5¢ -cactgacacgttggcagtgg-3¢ BC029618
Reverse: 5 ¢ -catggagaaggctggggctc-3¢
Cbfa-1 Forward: 5 ¢ -gtggacgaggcaagagtttca-3¢ NM_004348
Reverse: 5 ¢ -tggcaggtaggtgtggtagtg-3 ¢
Osterix Forward: 5 ¢ - ggcacaaagaagccgtactc-3¢ AF477981
Reverse: 5 ¢ - cactgggcagacagtcagaa-3¢
Collagen type I Forward: 5 ¢ -agggctccaacgagatcgagatccg-3¢ NM_000088
Reverse: 5 ¢ -tacaggaagcagacagggccaacgtcg-3¢
PTH-Receptor Forward: 5¢ -aggaacagatcttcctgctgca-3¢ X68596
Reverse: 5 ¢ -tgcatgtggatgtagttgcgcgt-3¢
Osteopontin Forward: 5¢ -ttgcttttgcctcctaggca-3 ¢ X13694
Reverse: 5 ¢ -gtgaaaacttcggttgctgg-3¢
Osteocalcin Forward: 5¢ -atgagagccctcacactcctc-3 ¢ X53698
Reverse: 5 ¢ -cgtagaagcgccgataggc-3 ¢
Lipoprotein Forward: 5¢ -atggagagcaaagccctgctc-3¢ NM_000237
lipase Reverse: 5¢ -gttaggtccagctggatcgag-3¢
PPAR g 2 Forward: 5 ¢ -ctcctattgacccagaaagc-3 ¢ D83233
Reverse: 5 ¢ -gtagagctgagtcttctcag-3 ¢
Leptin Forward: 5¢ -atgcattgggaaccctgtgc-3¢ NM_000230
Reverse: 5 ¢ -gcacccagggctgaggtcca-3¢
Collagen type II Forward: 5¢ -atgattcgcctcggggctcc-3¢ NM_033150
Reverse: 5 ¢ -cattactcccaactgggcgc-3 ¢
Collagen type X Forward: 5 ¢ -agccagggttgccaggacca-3¢ NM_000493
Reverse: 5 ¢ -ttttcccactccaggagggc-3 ¢
Aggrecan Forward: 5¢ -cactgttaccgccacttccc-3¢ NM_013227
Reverse: 5 ¢ -accagcggaagtccccttcg-3¢
Table 2. BM CFU-F express high levels of the STRO-1
antigen
No. of CFU-F 





STRO-1+ BMMNC were first isolated by MACS and then sorted according
to the level of STRO-1 expression, using FACS. The different FACS-sorted
STRO-1 fractions were then cultured under standard clonogenic conditions.
The data represent the mean number of day 14 CFU-F per 105 cells
plated±s.e.m. (n=5 different BM samples). 
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characterized by a high level of STRO-1 expression (STRO-
1BRIGHT) (Fig. 1B). By means of dual-colour cell sorting,
CFU-F were found to be restricted to the small proportion of
marrow cells co-expressing both antigens (STRO-
1BRIGHT/VCAM-1+) (data not shown). To determine the
incidence of CFU-F in the STRO-1BRIGHT/VCAM-1+
population, limiting dilution assays were performed. Analysis
of the data from six different marrow samples yielded a mean
frequency of approximately one CFU-F-derived colony ( ‡ 50
cells) per three STRO-1BRIGHT/VCAM-1+ cells, whereas the
incidence of all clonogenic CFU-F (measured as the sum of
colonies plus clusters) was one per two STRO-
1BRIGHT/VCAM-1+ cells plated (Fig. 1C), using Poisson
distribution statistics. Notably, of the 50% of wells deposited
with single STRO-1BRIGHT/VCAM-1+ cells that failed to
produce clones ( ‡ 10 cells), a significant proportion
(approximately 30%) contained either single or small groups
of stromal cells that failed to produce colonies or clusters (<10
cells) in these assay conditions. 
Characteristics of freshly isolated CFU-F
STRO-1BRIGHT/VCAM-1+ cells sorted directly from fresh,
marrow aspirates were large cells with heterochromatic nuclei
and prominent nucleoli, agranular cytoplasm and numerous
bleb-like projections of the cell membrane (Fig. 2A).
Ultrastructural analysis demonstrated an extensive array of
cytoplasmic microfilaments and a complex cell surface
morphology dominated by the bleb-like membrane protrusions
observed by light microscopy (Fig. 2B). Weibel-Palade bodies
characteristic of endothelial cells were not detected
in the enriched BMSSCs population. In addition,
Journal of Cell Science 116 (9)
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Fig. 1. Isolation and purification of BMSSCs. (A) Flow cytometric
analysis of MACS-sorted STRO-1+ marrow cells demonstrated
varying levels of STRO-1 expression. There were approximately
three distinct populations: dull (DULL), intermediate (INT) and
bright (BRT). (B) Dual-color flow cytometric analysis of VCAM-1
(PE) expression by STRO-1+ (FITC) marrow cells isolated by MACS
depicting a discrete population of STRO-1BRIGHT/VCAM-1+ cells
(region: R1), approximately 0.02% of the total BMMNC population.
(C) The incidence of clonogenic cell colonies (>50 cells) + clusters
(>10<50 cells) based on STRO-1BRIGHT/VCAM-1+ expression was
determined by limiting dilution analysis of 24 replicates per cell
concentration using Poisson distribution analysis (data derived from
six independent experiments). 
Fig. 2. Characterization of BMSSCs in vivo. (A) Light microscopic
examination of cytospins representing freshly sorted STRO-
1BRIGHT/VCAM-1+ marrow cells (1000· ) counterstained with
heamatoxylin. (B) Transmission electron micrograph depicting the
ultrastructure of freshly sorted STRO-1BRIGHT/VCAM-1+ cells
(15000· ). Immunohistochemical staining of cytospin preparations of
the sorted STRO-1BRIGHT/VCAM-1+ cells (1000· ) with collagen
type I (C) and a -SMA (D). (E) Dual-color flow cytometric analysis
of Ki67 (FITC) expression by STRO-1+ (PE) marrow cells isolated
by MACS. The majority of the STRO-1BRIGHT marrow cells lack
detectable binding of Ki67 relative to that of the isotype-matched
control antibody, indicated by the vertical quad-stat marker.
(F) Telomerase activity in different sorted cell populations was
examined using a modified TRAP assay. TRAP products derived
from CHAPS extracts of non-denatured (–) and denatured (+) total
BM (lanes 1), STRO-1BRIGHT/VCAM-1+ cells sorted fraction (lanes
2) and CD34+-sorted BM cells (lanes 3). TRAP products were
resolved on a 12% polyacrylamide gel, stained with SYBR green
fluorescent dye, and visualised using a fluorescence scanning system.
(G) A typical light microscopic view of a single purified STRO-
1BRIGHT/VCAM-1+ cell, allowed to adhere to fibronectin-coated
culture plates (400· ). (H) A representative example of a day 14
CFU-F colony stained with toluidine blue is shown (200 · ).
(I) Immunohistochemical staining showing all the cells that comprise
the CFU-F colony express collagen type I (200 · ).
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immunohistochemical staining of cytospin preparations of the
sorted STRO-1BRIGHT/VCAM-1+ marrow cells showed strong
staining in >90% of cells with anti-collagen type I antibody
(Fig. 2C) but failed to show any reactivity with antibodies to
factor-VIII-related antigen, a marker of vascular endothelial
cells, or to CD45, the common leukocyte antigen (data not
shown). A notable feature, however, was the expression of a -
smooth muscle actin ( a -SMA) in approximately 70% of
STRO-1BRIGHT/VCAM-1+ cells although the intensity of
immunostaining varied somewhat between individual cells
(Fig. 2D). 
Dual-colour flow cytometric analysis demonstrated that the
STRO-1BRIGHT population lacked detectable expression of the
Ki-67 antigen, demonstrating that these cells do not divide in
vivo (Fig. 2E). In addition, telomerase activity commonly
found in stem cell populations of other renewing tissues was
also present in the total STRO-1+ population isolated by MACS
and in the minor subpopulation of STRO-1BRIGHT/VCAM-1+
FACS-sorted cells (Fig. 2F). Following transfer of the sorted
cells in vitro, they rapidly attached and spread assuming a
stellate morphology with long processes (Fig. 2G) capable of
clonal expansion forming colonies consisting of collagen type
I positive fibroblast-like cells (Fig. 2H,I).
An essential feature of stem cell populations in all renewing
tissues is a capacity for extensive proliferation. Initial studies
to examine the proliferative potential of BMSSCs were
performed in which STRO-1BRIGHT/VCAM-1+ cells were
cultured in bulk and then serially passaged over the course of
a number of weeks in culture. This analysis reproducibly
demonstrated a cumulative expansion in the number of
adherent stromal cells for over 40 population doublings prior
to the onset of cellular senescence (data not shown). Since
these data reflect the proliferative activity of a mixed
population of BMSSCs, we chose to conduct a more rigorous
examination of the growth potential of individual STRO-
1BRIGHT/VCAM-1+ BMSSCs obtained by means of the single
cell deposition unit of the cell sorter. A total of 35 CFU-F
colonies derived from two BM samples were expanded in
culture, as above, and analysed for their cumulative production
of cells over a number of weeks in culture. There was marked
variation in proliferative capacity between individual CFU-F
(Fig. 3). The majority of clones (29/35; 83%) exhibited only
moderate growth potential that did not persist beyond 20
population doublings. In contrast, a minor proportion of clones
(6/35, 17%) demonstrated continued growth, extending beyond
20 population doublings, generating a mean of 3.0 · 108 cells
per BMSSCs (range, 9.8 · 106 – 5.2· 108 cells). At this time,
cells derived from highly proliferative clones (>20 population
doublings) were analyzed for their expression of STRO-1 and
VCAM-1 by flow cytometry. Although VCAM-1 expression
was retained by the progeny of the initiating cells, the STRO-
1 epitope was expressed by only a minor subpopulation in all
clones analysed (range 3.2-15.8%; median 5.3%; n=6).
Gene expression profile of CFU-F in vivo and following
proliferation and differentiation in vitro
We first surveyed the pattern of gene expression in freshly
isolated STRO-1BRIGHT/VCAM-1+ BMMNC by means of RT-
PCR. There was no detectable expression of mature bone
markers such as osteopontin, parathyroid hormone-receptor
nor osteocalcin. Importantly, this population also lacked the
expression of the essential early bone-cell-specific
transcription factors CBFA1 and osterix (Fig. 4). A similar
analysis of mRNA transcripts with restricted expression in
adipose cells revealed constitutive expression of only

















Fig. 3. Proliferation potential
of BMSSC clones. A total of
35 CFU-F colonies derived
from STRO-1BRIGHT/VCAM-
1+ single sorted cells from
two BM samples were
analysed for their cumulative
production of cells. A marked
variation in proliferative
capacity between individual
BMSSCs is evident. The
majority of clones (29/35,
83%) exhibited only
moderate growth potential,
which did not persist beyond





Fig. 4. Gene expression profile
of BMSSCs in vivo and
following differentiation in
vitro. RT-PCR analysis of gene
expression in STRO-1BRIGHT/VCAM-1+-purified BMSSCS isolated
directly from marrow aspirates (1), and when cultured in regular
growth medium (2) or medium inductive for either for bone, fat or
cartilage development (3) as described in Materials and Methods.
The expression of a range of markers characteristic of each tissue is
shown. Bone: transcription factors CBFA1 and osterix (OSX),
collagen type I (COL-1), osteopontin (OPN), osteocalcin (OCN) and
parathyroid hormone receptor (PTH-R). Fat: lipoprotein lipase
(LPL), transcription factor PPARg 2 and leptin. Cartilage: collagen
type II (COL-II), collagen type X (COL-X) and aggrecan (AGGN).
Reaction mixes were subjected to electrophoresis on a 1.5% agarose
gel and visualised by ethidium bromide staining. RNA integrity was
assessed by GAPDH expression.
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including, leptin and the early adipocytic transcription factor,
PPARg 2 (Fig. 4). Finally, expression analysis of genes
restricted to the chondrocyte lineage demonstrated neither
collagen type II nor aggrecan expression although collagen
type X, a marker associated with hypertrophic chondrocytes,
was consistently detected (Fig. 4).
Next, bulk cultures initiated with STRO-1BRIGHT/VCAM-1+
cells were expanded by passaging two to three times, at which
point aliquots of cells were plated in conditions previously
described to induce osteogenic (Gronthos et al., 1994),
adipogenic (Gimble, 1998) and chondrogenic (Pittenger et al.,
1999) differentiation of BMSSCs in vitro. Expression of
CBFA-1, osterix and osteopontin were detected by RT-PCR in
both induced and non-induced control cultures (Fig. 4),
whereas osteocalcin and PTH-R transcripts were detected
within 4-5 weeks of growth in osteoinduction media.
Following 2-3 weeks of adipogenic induction, transcripts were
detected for the fat-associated markers, PPARg 2 and leptin
(Fig. 4). Similarly, in aggregate cultures, prolonged exposure
to TGFb 3 induced the mRNA expression of the cartilage-
associated matrix components collagen type II and aggrecan
by RT-PCR (Fig. 4).
Developmental potential of BMSSC clones in vitro and in
vivo
Comparison of the in vitro developmental potential of 64
highly proliferative BMSSC clones (20 population doublings),
derived from single STRO-1BRIGHT/VCAM-1+ cells (n=3
marrow samples), demonstrated the formation of von Kossa
positive mineralized deposits by all clones in vitro after several
weeks under osteogenic-induction conditions (Fig. 5A).
Similarly, 95% of the same BMSSC clones formed clusters of
Oil red O-positive lipid-laden adipocytes when cultured in
adipogenic inductive media (Fig. 5B). A sample of 20 high
proliferative clones were assayed for their chondrogenic
potential using the well established aggregate culture system
(Pittenger et al., 1999) in the presence of TGF b 3. Again, all
clones exhibited synthesis of collagen type II by
immunohistochemistry (Fig. 5C). However, with continuous
subculture (greater than 25 population doublings) the BMSSCs
clones showed either a reduced capacity or an inability to
differentiate into all three stromal cell lineages (data not
shown).
The capacity to develop a mineralised matrix in vitro,
although consistent with osteogenic differentiation, may
nevertheless not predict the capacity of the cells to produce an
organised bone tissue in vivo. In view of this concern, all 64
highly proliferative BMSSC clones were assayed for their
capacity to develop human bone tissue following ectopic
transplantation in SCID mice, using hydroxyapatite/tricalcium
phosphate (HA/TCP) particles as a carrier vehicle (Gronthos
et al., 2000; Kuznetsov et al., 1997). Histiological examination
at week 8 showed that all of the implants contained an
extensive network of blood vessels and fibrous tissue (Fig. 6A).
Bone formation was evident in 35/64 clones (54%), whereas
associated haematopoietic marrow/adipose elements were
observed in 11/35 of the bone-producing clones (31%).
Cartilage development, as assessed by immunohistochemical
staining with an antibody to collagen type II, was not detected
in any implant. The origin of the cellular material within the
recovered implants was assessed by in situ hybridization using
a probe to the unique human repetitive alu. The interstitial
tissue, bone lining cells and osteocytes within the newly
formed bone were found to positive for the alu sequence,
confirming their human origin (Fig. 6B). Conversely, neither
the endothelium-lining small blood vessels, haematopoietic
cells nor the adipose and muscle tissue surrounding the
HA/TCP carrier demonstrated hybridization with the alu probe
and were therefore presumed to be of murine origin.
Discussion
A large body of evidence demonstrates that stromal tissue
derived from adult BM of avian and mammalian species
contains clonogenic progenitor cells (CFU-F), some of which
are considered to be multi-potent BMSSCs with the capacity
to differentiate into a range of mesenchymal cell lineages
including adipose tissue, bone, cartilage, tendon and ligament
(Bruder et al., 1994; Prockop, 1997). Despite considerable
interest in the potential therapeutic applications of these cells,
there is no well-defined protocol for the prospective isolation
of human CFU-F in order to properly study their biological
properties prior to cell culture. Current methodologies for the
isolation of primitive BMSSCs are based upon those initially
described by Friedenstein and colleagues, which rely upon
the rapid adhesion of the stromal progenitor populations to
tissue culture plastic and their subsequent rapid proliferation
in vitro (Castro-Malaspina et al., 1980; Friedenstein et al.,
1970; Kuznetsov et al., 1997; Pittenger et al., 1999). Such
protocols result in a heterogeneous starting population of
adherent BM cells, of which only a minor proportion
represent multipotent BMSSCs. Moreover these protocols
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Fig. 5. Developmental potential
of BMSSCs in vitro. Primary
cultures of cells derived from
STRO-1BRIGHT/VCAM-1+
marrow cells were induced under
osteogenic, adipocytic or
chondrocytic conditions.
(A) Mineralized deposits stained
positively with the von Kossa
reagent (arrow) formed within 4
weeks of culture under
osteoinductive conditions
(200 · ). (B) The presence of
clusters of lipid containing
adipocytes were also detected by
Oil red-O staining (arrow) within
2 weeks of adipogenic induction
(200 · ). (C) In aggregate
cultures, collagen type II was
present throughout the cellular
mass following 3 weeks of
chondrogenic induction (arrow)
(200 · ).
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select for the progeny of CFU-F and not for the clonogenic
progenitors themselves. 
In this report, we describe the isolation of a minor
subpopulation of adult human BMMNC that represent a near
homogeneous population of CFU-F. This was achieved using
the CFU-F reactive antibody STRO-1 (Simmons and Torok-
Storb, 1991) in combination with an antibody to VCAM-1, a
cell adhesion molecule constitutively expressed by marrow
stromal tissue in vitro and in vivo (Simmons et al., 1992) and
also by CFU-F (Simmons et al., 1994). This approach enabled
the resolution of a discrete subpopulation of STRO-
1BRIGHT/VCAM-1+ marrow cells with a cloning efficiency for
CFU-F approaching 50% using Poisson distribution statistics.
This degree of enrichment for CFU-F in the STRO-
1BRIGHT/VCAM-1+ cell fraction (approximately 5,000-fold
relative to unfractionated BM) substantially exceeds that
previously reported for any mammalian species including mice
and humans (Castro-Malaspina et al., 1980; Simmons and
Torok-Storb, 1991; Van Vlasselaer et al., 1994; Waller et al.,
1995). A significant factor contributing to the success of this
enrichment strategy is the use of our previously defined serum-
deprived culture conditions for the assay of CFU-F, in which
colony growth at low plating densities is stimulated by the
addition of a combination of EGF and PDGF-BB (Gronthos
and Simmons, 1995). CFU-F are generally assayed in medium
supplemented with FCS as a growth stimulus. Although this is
adequate for CFU-F growth from unfractionated bone marrow
at high plating densities, when more enriched cell populations
are assayed in FCS-containing medium, growth of CFU-F
becomes suboptimal, particularly at limiting cell
concentrations (Gronthos and Simmons, 1995). Indeed, in the
current study, STRO-1BRIGHT/VCAM-1+ CFU-F failed to grow
in foetal bovine serum supplemented medium at plating
densities <10 cells per well (data not shown), whereas in the
serum-deprived assay, a significant proportion of cells
exhibited clonogenic growth even when plated at 1 cell per
well. It is important to note, however, that even under these
highly efficient culture conditions a significant proportion of
single STRO-1BRIGHT/VCAM-1+ cells, although failing to
proliferate sufficiently to qualify as either clusters or colonies,
nevertheless contained stromal cells that either remained as
single cells or underwent one or two divisions only. The nature
of the STRO-1BRIGHT/VCAM-1+ stromal cells that fail to either
proliferate or do so only poorly remains to be determined. One
possibility is that expression of the antigen identified by STRO-
1 may encompass not only stromal progenitors but also
partially differentiated stromal cells with correspondingly
reduced growth potential in vitro. Alternatively, these cells may
represent a subpopulation of stromal progenitors that fail to
proliferate in these assay conditions. Nevertheless, the STRO-
1BRIGHT/VCAM-1+ BMMNC represent a virtually pure
population of collagen type I positive, stromal progenitor cells
with varying clonogenic efficiencies.
As a population, STRO-1BRIGHTVCAM-1+ cells have
several important phenotypic characteristics previously
attributed to stem cells in other renewing tissues (Fuchs and
Segre, 2000). Firstly, freshly isolated BMNC-derived STRO-
1BRIGHT cells lacked expression of the Ki-67 antigen and thus
appear to be a non-cycling population in vivo. This is in accord
with previous studies demonstrating the quiescent nature of
CFU-F in unfractionated rodent and human BM (Castro-
Malaspina et al., 1981; Falla et al., 1993). Secondly, STRO-
1BRIGHTVCAM-1+ cells and their progeny constitutively
exhibit telomerase activity, a well documented feature of stem
cell populations in renewing tissues that is lost during normal
somatic cell proliferation and differentiation (Fuchs and Segre,
2000; Harle-Bachor and Boukamp, 1996). Recent studies have
shown that human BMSSCs lose telomerase activity during ex
vivo expansion, whereas enforced telomerase activity greatly
enhanced the proliferative life-span and osteogenic potential of
cultured BMSSCs (Shi et al., 2002; Simonsen et al., 2002).
Thirdly, freshly sorted STRO-1BRIGHTVCAM-1+ cells exhibit
an undifferentiated phenotype as demonstrated by the absence
of gene products characteristic of endothelial cells and mature
stromal elements such as osteogenic cells, adipocytes and
chondrocytes within the BM. Most significantly in this regard,
this population lacked detectable expression of transcription
factors with pivotal roles in the early differentiation of bone
(CBFA-1, osterix) and adipose (PPAR g 2) tissues and the
signature marker of chondrocytes, collagen type II (Ducy et al.,
1997; Nakashima et al., 2002; Tontonoz et al., 1994). 
A notable feature of the BM CFU-F population is the
considerable heterogeneity in their potential for differentiation
Fig. 6. Developmental potential of BMSSCs clones in vivo.
Immunoselected STRO-1BRIGHT/VCAM-1+ marrow-derived clones
were expanded in vitro, then implanted subcutaneously into SCID
mice using HA/TCP carrier. Implants were harvested 8 weeks after
the transplant. (A) New bone formation containing osteocytes
(arrow) was observed for a proportion of clones developing at the
HA/TCP particle surfaces together with surrounding fibrous and
hematopoietic tissue (BM). The sections were counter stained with
haematoxylin and eosin (200 · ). (B) The osteocytes and bone lining
cells (arrow) were found to be of human origin, as demonstrated by
in situ hybridization using a DNA probe specific to the human alu
repeat sequence (200 · ).
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and proliferation. In accord with the putative stromal stem cell
hierarchy of cellular differentiation, we found that only a
proportion of the STRO-1BRIGHT/VCAM-1+ cell population
was capable both of extensive proliferation in vitro beyond 20
population doublings and of differentiation into at least five of
the cellular components of BM stromal tissue, namely
myelosupportive stroma, smooth muscle cells, osteoblasts,
adipocytes and chondroblasts. Similar observations were
previously reported (Pittenger et al., 1999) for a population of
plastic adherent fibroblast-like cells comprising 0.01-0.001%
of nucleated cells in human BM. 
We have previously demonstrated that all CFU-F clones
derived from STRO-1+ human marrow demonstrated the
capacity to synthesise a mineralized bone matrix in vitro,
whereas only 48% of clones showed the capacity to form
adipocytes in vitro (Gronthos et al., 1994). In the present study,
highly proliferative clones, derived from single STRO-
1BRIGHTVCAM-1+ cells, exhibited osteogenic, chondrogenic
and adipogenic cell differentiation in vitro. However, when
assayed in SCID mice for their capacity to generate human
bone tissue following xenogeneic transplantation (Gronthos et
al., 2000; Kuznetsov et al., 1997) only a little over half of the
clones exhibited the potential to form bone in vivo. Thus the
in vitro culture assay, despite evidence of many of the
phenotypic characteristics of differentiated bone cells
including expression of the master control gene CBFA1, does
not accurately predict the osteogenic potential of BMSSCs
clones in vivo, in accord with studies on murine BM stromal
cell lines (Satomura et al., 2000). Use of the more stringent in
vivo assay demonstrated that osteogenic differentiation is only
exhibited by a subpopulation of clones and is consistent with
the findings of Kusnetsov and colleagues (Kuznetsov et al.,
1997).
In the present study, the data indicate that CFU-F in adult
human BM represent a mixed population of multi-, bi- and uni-
potential progenitors at different stages of differentiation, as
initially proposed by Owen and Friedenstein (Owen and
Friedenstein, 1988) and subsequently supported by others
(Kuznetsov et al., 1997; Pittenger et al., 1999). Future studies
designed to subset the STRO-1BRIGHTVCAM-1+ population
may in time reveal a minor population with properties attributed
to pluripotent stem cells. Efforts to identify BMSSCs in vivo
have been hampered by the lack of precise knowledge regarding
their anatomical distribution within the marrow. It has been
suggested that that osteoprogenitors may be associated with the
outer surfaces of the marrow vasculature (Bianco et al., 2001).
In the present study, STRO-1BRIGHTVCAM-1+ cells proved to
be a homogeneous population of large collagen type I positive
cells lacking phenotypic characteristics of leukocytes or
vascular endothelial cells. Of particular note is the expression
of a -SMA by this population. In adult human BM in vivo, a -
SMA is limited to vascular smooth muscle cells in the media
of arteries, cells lining the abluminal surface of sinuses,
pericytes lining capillaries and occasional flattened cells on the
endosteal surface of bone. Expression of a -SMA is not detected
in other marrow stromal elements such as reticular cells within
haemopoietic cords, adipocytes or vascular endothelial cells
(Galmiche et al., 1993). Collectively these observations suggest
two possibilities for the identity and anatomical location of
stromal progenitors in the BM: vascular smooth muscle
cells/pericytes and endosteal cells. Furthermore, accumulating
data suggest that vascular pericytes may also fulfil the role of
multipotential mesenchymal progenitors (Doherty et al., 1998;
Schor et al., 1995). 
The biological properties of the BMSSCs described herein
should be viewed in the context of recent reports that
demonstrate that the inherent developmental potential of stem
cells derived from various mammalian tissues may be more
similar than previously suspected (Azizi et al., 1998; Bjornson
et al., 1999; Gussoni et al., 1999). This suggests that the
developmental plasticity of stem cells is dictated by the local
tissue microenvironment in which they lodge, and it would
therefore be of great interest to examine whether the population
of candidate stem cells described herein can regenerate tissues
other than the marrow stroma and associated skeletal tissues
(Prockop, 1997). It is conceivable therefore that the properties
exhibited by the STRO-1BRIGHTVCAM-1+ population may, in
time, be useful for a range of novel cellular therapies that
extends beyond their more obvious use in the treatment of
disorders of the haemopoietic and skeletal systems. 
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